Csf2

Overview

Csf2 is the gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), a pleiotropic cytokine that regulates hematopoiesis, myeloid cell differentiation, survival, and inflammatory activation. In biomedical literature, Csf2 is commonly discussed as an immune signaling molecule rather than as a structural protein or enzyme. Its activity is mediated through the GM-CSF receptor complex, influencing monocytes, macrophages, neutrophils, and other myeloid-lineage cells.

Functionally, Csf2 is relevant to both normal immune homeostasis and disease-associated inflammation. It has been studied in cancer immunotherapy as an adjuvant or immune-modulating component, and in inflammatory and tissue-injury settings where excessive or dysregulated GM-CSF signaling can contribute to pathology. Recent work also places Csf2 within broader cytokine networks, including pathways involving CXCL-CXCR2 signaling and neutrophil programming, as well as combination strategies with therapies such as anti-NB vaccine approaches and naxitamab in neuroblastoma.

Focus of Latest Publications

Recent publications involving Csf2 have focused primarily on its role as granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunotherapy and inflammatory signaling. In cancer studies, GM-CSF was used as an immune adjuvant or engineered payload in combination approaches designed to enhance antitumor responses. One randomized phase II melanoma trial evaluated a multipeptide vaccine with or without GM-CSF and with one- or two-site administration, with the publication reporting long-term clinical outcomes from that study. Another phase II neuroblastoma trial assessed naxitamab plus stepped-up GM-CSF dosing as consolidation therapy for patients in second or later complete remission, concluding that the combination was a good option for consolidating post-relapse remission, while noting that the encouraging long-term outcome could not be attributed solely to naxitamab plus GM-CSF because of additional post-protocol therapies.

Csf2 was also studied in the context of oncolytic virus-based immunotherapy. In ovarian cancer and non-small cell lung cancer cell line models, modified oncolytic viruses were engineered to express GM-CSF or ICOSL and were combined with an EGFRxCD16 bispecific antibody to assess NK cell activation, degranulation, cytokine production, and cytotoxicity. The study found that the bispecific antibody was the main driver of NK-cell activation, while the viruses alone had limited direct impact on NK cells; however, tumor preconditioning with oncolytic viruses, especially ONCOS-102, together with the EGFRxCD16 antibody produced the strongest NK-cell cytotoxicity, including against ovarian and EGFR-mutant lung tumor cell lines.

Beyond immunotherapy, Csf2 was implicated in inflammatory lung injury. A study on radiation-induced lung injury reported that CSF2 drives the condition by eliciting PADI4-high pathogenic neutrophils, highlighting a mechanism of crosstalk between damaged epithelial cells and neutrophils in the lung microenvironment. In colorectal cancer, CSF signaling appeared within a tumor microenvironment interaction network: integrated single-cell, bulk RNA-seq, and spatial transcriptomic analyses identified an EREG/EGFR/CSF axis in EGFR inhibitor-eligible tumors, in which cancer-cell-derived EREG stimulated EGFR-expressing cancer-associated fibroblasts that then signaled via CSF to tumor-associated macrophages/monocytes, potentially promoting M2 polarization.